Working… Menu

The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01250548
Recruitment Status : Completed
First Posted : December 1, 2010
Last Update Posted : September 3, 2014
Information provided by (Responsible Party):
Baylor Research Institute

Brief Summary:

The purpose of this study is to compare the effects of apremilast with a placebo (an inactive substance that looks like apremilast) on you and other people with rheumatoid arthritis.

The investigators will be collecting information in this study to help us determine -

  • the safety of apremilast in patients with active rheumatoid arthritis
  • how long it takes for patients with active rheumatoid arthritis to respond to apremilast
  • how long the effects of apremilast last after the treatment has ended.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Biological: apremilast Other: Placebo Phase 2

Detailed Description:

Many manifestations associated with RA result from, or are significantly influenced by, the effects of pro-inflammatory cytokines (e.g., TNF, IL-1, IL-6). Specific inhibition of these cytokines with newer, parenterally administered biologic agents has revolutionized the treatment of RA. Apremilast is a novel, orally administered drug which approaches the reduction of pro-inflammatory cytokines via inhibition of phosphodiesterase type 4 (PDE4).

Apremilast, Acetamide, N-[2-[ (1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl) ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl] is a phosphodiesterase type 4 (PDE4) inhibitor under development for use in the treatment of inflammatory conditions.

PDE4 is one of the major phosphodiesterases expressed in leukocytes. Inhibitors of PDE4 cause accumulation of intracellular cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A and other downstream effectors, resulting in inhibition of pro-inflammatory cytokine transcription and other cellular responses such as neutrophil degranulation, chemotaxis, and adhesion to endothelial cells.

In human cellular models, apremilast inhibited production of inflammatory mediators such as TNF-α, IL-12, IL-2, IFN-γ, IL-5, IL-8, leukotriene B4 (LTB4), and the adhesion molecule CD18/CD11b (Mac-1).

Apremilast has also been shown to be a potent anti-inflammatory agent in several animal models of inflammation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment
Study Start Date : May 2010
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Apremilast

Arm Intervention/treatment
Active Comparator: 2 Biological: apremilast
30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks

Placebo Comparator: Apremilast
Placebo Compared to apremilast arm
Other: Placebo

Primary Outcome Measures :
  1. To determine the time to response for subjects with active RA taking apremilast (30 mg per os [PO], twice per day [BID]) [ Time Frame: 1.5 years ]

Secondary Outcome Measures :
  1. Determine time to flare when apremilast is withdrawn [ Time Frame: 1.5 years ]
  2. Assess the efficacy and magnitude of response to apremilast in active RA measured by ACR 20, 50, & 70 response rates [ Time Frame: 2 years ]
  3. Assess safety of apremilast in subjects with active RA [ Time Frame: 2 years ]
    Review of labs and possible adverse effects of study drug including Data Safety Monitoring Committee analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must be able to adhere to the study visit schedule and other protocol requirements
  • documented rheumatoid arthritis (RA) diagnosis by the 1987 American College of Rheumatology (ACR) criteria for at least 6 months
  • disease duration 6 or more months (from symptom onset)
  • failed 1 or more DMARD
  • active RA despite current DMARD therapy; active disease defined as 4 or more tender and 4 or more swollen joints (out of 28 joints examined) and any one of the following:
  • ESR 28 or higher mm/hr;
  • CRP 1.0 or more mg/dl;
  • Morning stiffness 45 or more minutes.
  • Patients receiving DMARD or biologic therapy must undergo a drug washout.
  • Patients receiving a nonsteroidal anti-inflammatory drug (NSAID) and/or prednisone (10 or less mg day) must be on stable doses of these agents for more than 2 weeks.
  • Must meet laboratory criteria as specified in the protocol
  • Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening and must adhere to adequate forms of contraception as defined in the protocol. Must agree to pregnancy tests every 28 days while on study medication.
  • Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in sexual activity with FCBP while on study medication and for 28 days after taking the last dose of study medication

Exclusion Criteria:

  • Inability to provide voluntary consent
  • History of any clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, neurologic, gastrointestinal, immunologic, or other major diseases
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Pregnant or breastfeeding female
  • Systemic fungal infection
  • Active tuberculosis (TB) or a history of incompletely treated tuberculosis.
  • History of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment within the past 2 years)
  • Clinically significant abnormality on the chest x-ray (CXR) at screening. Chest x-rays performed within 3 months prior to start of study drug are acceptable.
  • Use of any investigational medication within 28 days prior to randomization or 5 half-lives if known (whichever is longer)
  • Any clinically significant abnormality on 12-lead ECG at screening
  • History of congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency [CVID])
  • History of Human Immunodeficiency Virus (HIV) infection
  • Presence of hepatitis B surface antigens (HBsAg) or Hepatitis core antibody positive at screening.
  • Antibodies to Hepatitis C virus at screening
  • History of malignancy within 5 years prior to the screening visit (except for treated [i.e. cured] basal cell skin carcinomas and treated [i.e. cured] carcinoma in situ of the cervix)
  • currently on DMARD therapy
  • currently taking biologics
  • treated with rituximab in the last 6 months
  • Recent hospitalization (last 3 months)
  • Planned pregnancy or major surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01250548

Layout table for location information
United States, Texas
Baylor Research Institute - Arthritis Care and Research Center
Dallas, Texas, United States, 75231
Sponsors and Collaborators
Baylor Research Institute
Layout table for investigator information
Principal Investigator: John Cush, MD Baylor Research Institute
Layout table for additonal information
Responsible Party: Baylor Research Institute Identifier: NCT01250548    
Other Study ID Numbers: 009-293
First Posted: December 1, 2010    Key Record Dates
Last Update Posted: September 3, 2014
Last Verified: September 2014
Keywords provided by Baylor Research Institute:
Rheumatoid arthritis
Active rheumatoid arthritis
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Phosphodiesterase 4 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action